BioSpace News Archive

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2023 financial results on Thursday, August 3, 2023, after the U.S. financial markets close.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 130,050 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Bio-Rad Laboratories, Inc. announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock.

Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.

For the third straight quarter, San Francisco Health Plan (SFHP) is ranked number one among managed care plans for Medi-Cal COVID-19 vaccination rates.

23andMe Holding Co. released a new Simvastatin Medication Insight report as part of its 23andMe+ membership service that reports on a person’s likelihood of experiencing side effects from this commonly prescribed statin drug.

Co-Diagnostics, Inc. announced today that it is hosting a booth at the American Association for Clinical Chemistry (AACC) annual meeting and expo held July 23-27, 2023.

EASEE®, the world’s first minimally invasive brain pacemaker, presented by Angela Liedler, CEO of Heidelberg-based Precisis, has been awarded top prize in this year’s ‘Shark Tank’ competition run by the Epilepsy Foundation.

Champions Oncology, Inc. will report its financial and operational results for the fourth quarter and year ended April 30, 2023, on Monday, July 24, 2023, after market close.

ImmunityBio, Inc., a clinical-stage immunotherapy company, announced that it has executed financing to provide further working capital and support its ongoing business operations.